Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline PK and Safety in Pediatric Bacterial Infections
NCT05217537Phase 1Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Feb 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of omadacycline in bacterial infection, sponsored by Paratek Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 48 hours After IV Infusion, Area Under the Plasma Concentration Versus Time Curve From Time 0 to 48 hours After Oral Administration and 10 more. Started Apr 2022; status: completed.
02
Drugs
omadacycline
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05217537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217537.